nach oben

PharmacoEconomics

Erschienen in:

01.06.2005 | Review Article

Pharmacoeconomic evaluation of antidepressants

A critical appraisal of methods

verfasst von: Dr Sheikh Usman Iqbal, Mark Prashker

Erschienen in: PharmacoEconomics | Ausgabe 6/2005

Einloggen, um Zugang zu erhalten

Abstract

In recent years, there has been much debate regarding the real cost effectiveness of new antidepressants. This review is an attempt to identify key contentious methodological issues that can impact the reliability, validity and quality of the research on this subject. There are inherent complexities between inputs and outcomes related to depression, and the choice of pharmacoeconomic methodology requires a crucial balance between the study design and its ability to capture relevant information. Knowledge of the real efficiency of antidepressants should always be ascertained with reference to the real-world setting. Studies that show a corresponding balance between internal and external validity, coupled with sound methodology and standardised reporting, have the potential to translate pharmacoeconomics research into real-world, time-relevant decision-making.

Drummond ME O’Brien B, Stoddart GL, et al. Methods for economic evaluation of health care programmes. New York: Oxford University Press Inc., 1997

Motheral B, Brooks J, Clark MA, et al. A checklist for retrospective database studies: report of the ISPOR Task Force on Retrospective Database. Value Health 2003; 6: 90–7PubMedCrossRef

Hylan TR, Crown WH, Meneades L, et al. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis. J Affect Disord 1998; 47: 71–9PubMedCrossRef

Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 1994; 16: 715–30PubMed

Simon GE, Fishman P. Cost implications of initial antidepressant selection in primary care. Pharmacoeconomics 1998; 13: 61–70PubMedCrossRef

Forder J, Kavanagh S, Fenyo A. A comparison of the costeffectiveness of sertraline versus tricyclic antidepressants in primary care. Affect Disord 1996; 38: 97–111CrossRef

Melton ST, Kirkwood CK, Farrar TW, et al. Economic evaluation of paroxetine and imipramine in depressed outpatients. Psychopharmacol Bull 1997; 33: 93–100PubMed

Bhaumik S, Branfold D, Dugginala C, et al. A naturalistic study of the use of antidepressants in adults with learning disabilities and affective disorders. Leicester: Frith Hospital, 1995

Roose SP, Glassman AH, Attia E, et al. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994; 151: 735–1739

10.

Crown WH. Economic outcomes associated with tricyclic antidepressant and selective serotonin reuptake inhibitor treatments for depression. Acta Psychiatr Scand 2000; 101 Suppl. 403: 62–6CrossRef

11.

Lader M. Current trends in drugs for depression. Update 1996; 52: 149–53

12.

Antonuccio DO, Danton WG. Psychotherapy versus medication for depression: challenging the conventional wisdom with data. Prof Psychol Res Pr 1995; 26: 574–85CrossRef

13.

Stewart A. Choosing an antidepressant: effectiveness based pharmacoeconomics. J Affect Disord 1998; 48: 125–33PubMedCrossRef

14.

Vonkorff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992; 45: 197–203CrossRef

15.

Katzeinick DJ, Koback KA, Jefferson JW, et al. Prescribing patterns of antidepressant medications for depression in a HMO. Formulary 1996; 31: 374–88

16.

Rosholm JU, Gram LF, Isacsson G, et al. Changes in the pattern of antidepressant use upon the introduction of the new antidepressants: a prescription database study. Fur J Clin Pharmacol 1997; 52: 205–9CrossRef

17.

Sclar DA, Skaer TL, Robison LM, et al. Evidence based algorithm for antidepressant pharmacotherapy. JAMA (Sea) 1997; 13: 33–40

18.

Katon W, Von Korff M, Lin E. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992; 30: 67–76PubMedCrossRef

19.

Bruce EL, Haiden AIL Carol T, et al. The evolution of quality management in state Medicaid agencies: a national survey of states with comprehensive managed care programs. It Comm J Qual Improv 2002; 28: 426–36

20.

Lin EH, Von KM, Katon W, et al. The role of the primary care physician in patients’ adherence to antidepressant therapy. Med Care 1995; 33: 67–4PubMedCrossRef

21.

Einarson TR, Arkian S, Sweeney S, et al. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders. Clin Ther 1995; 17: 136–53PubMedCrossRef

22.

Jonsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 164: 665–73PubMedCrossRef

23.

Einarson TR, Addis A, Iskedjian M. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. Pharmacoeconomics 1997; 12: 286–96PubMedCrossRef

24.

Doyle J, Casciano J, Arkinian S, et al. The health economic impact of antidepressant usage from a payer’s perspective: a multinational study. Int J Clin Pract 2001; 55: 292–9PubMed

25.

Lapierre Y, Bentkover J, Schainbum S, et al. Direct costs of depression: analysis of treatment costs of paroxetine versus imipramine in Canada. Can J Psychiatry 1995; 40: 370–7PubMed

26.

Nutjen MJC, Hardens M, Soutre E. A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression. Pharmacoeconomics 1995; 8: 159–68CrossRef

27.

New evidence-based treatments for depression. Proceedings of the Magellan Behavioral Health 2001 Clinical Medical Retreat. Managed Care 2001; 10 (Spec Suppl): 1–25

28.

Johnson DA. Treatment compliance in general practice. Acta Psychiatr Scand 1981; 63 Suppl. 209: 447–53CrossRef

29.

Judith RL, Richard GF, Herbert CS, et al. Cost-effectiveness of treatments for major depression in primary care practice. Arch Gen Psychiatry 1998; 55: 645–51CrossRef

30.

Freemantle N, House A, Song F. Prescribing selective serotonin reuptake inhibitors as a strategy for prevention of suicide. BMJ 1994; 309: 249–53PubMedCrossRef

31.

Therese MC, Crismon ML, Daniel IS. A critical review of selected pharmacoeconomic analyses of antidepressant therapy. Ann Pharmacother 1999; 33: 364–72CrossRef

32.

Sclar DA, Skaer TL, Robison LM, et al. Economic appraisal of antidepressant pharmacotherapy: critical review of the literature and future directions. Depress Anxiety 1998; 8 Suppl. 1: 121–7PubMedCrossRef

33.

Hotopf M, Lewis G, Normand C. Are SSRIs a cost-effective alternative to tricyclics? Br J Psychiatry 1996; 306: 683–7

34.

Agency for Health Care Policy Research (AHCPR) Depression Guideline Panel. Treatment of Major Depression (Depression in primary care 2) Clinical Practice Guideline 5. Rockville (MD): US Department of Health and Human Services, Public health Service, AHCPR, 1993. AHCPR Publication 93-0550

35.

John AH Carol AR. Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Pharmacoeconomics 1997; 11: 515–37CrossRef

36.

Anderson UA, Andersen M, Rosholm JU, et al. Psychopharmacological treatment and psychiatric morbidity in 390 cases of suicide with special focus on affective disorders. Acta Psychiatr Scand 2001; 104: 458–65CrossRef

37.

Jick SS, Dean AD, Jick H. Antidepressants and suicide. BMJ 1995; 310: 215–8PubMedCrossRef

38.

Hale AS. The importance of accidents in evaluating the cost of SSRIs: a review. Int Clin Psychopharmacol 1994; 9: 195–201PubMedCrossRef

39.

Crott R, Gilis P. Economic comparisons of the pharmacotherapy of depression: an overview. Acta Psychiatr Scand 1998; 97: 241–52PubMedCrossRef

40.

Minshall ME, Kody MC, Mosbacher F. Pharmacoeconomics research credibility: a controversial and recurring theme in health outcomes research. Med Care 1999; 37: 12–9CrossRef

41.

Skaer TL, Sclar DA, Robison LM, et al. The need for an iterative process for assessing economic outcomes associated with SSRIs. Pharmacoeconomics 2000; 18: 205–14PubMedCrossRef

42.

Curran HV, Sakulsripong M, Lader M. Antidepressants and human memory: an investigation of four drugs with different sedative and anticholinergic profiles. Psychopharmacology (Berl) 1988; 95: 520–7CrossRef

43.

Peselow ED, Corwin J, Fieve RR. Disappearance of memory deficits in outpatient depressives responding to imipramine. J Affect Disord 1991; 21: 173–83PubMedCrossRef

44.

Jacobson F. Fluoxetine induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992; 53: 119–22

45.

Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62PubMedCrossRef

46.

Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278–96PubMedCrossRef

47.

Matthew H, Glyn L, Charles N. Putting trials on trial-the costs and consequences of small trials in depression: a systematic review of methodology. J Epidemiol Community Health 1997; 51: 354–8CrossRef

48.

Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993; 2: 32–5

49.

Conti DJ, Burton WN. Economic impact of depression in a workplace [abstract]. J Occup Environ Med 1994; 36: 983–8

50.

Rand Corporation. The course of depression in adult outpatients: results from the medical outcomes study. Arch Gen Psychiatry 1992; 49: 788–94CrossRef

51.

National Mental Health Association and Employee Assistance Professionals Association. Depression: its effects on the work force. Exchange 1996; 26: 5

Titel: Pharmacoeconomic evaluation of antidepressants
A critical appraisal of methods
verfasst von: Dr Sheikh Usman Iqbal
Mark Prashker
Publikationsdatum: 01.06.2005
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 6/2005
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200523060-00006

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2005

Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease

Remission from depression

The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK

The economics of topical immunomodulators for the treatment of atopic dermatitis

Incorporation of uncertainty in health economic modelling studies

Bipolar disorder and health-related quality of life